Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum.
AFT Group Sales Growth continues at +40%
Similar articles
APP 2018 Competition
Thank you for visiting the AFT Pharmaceuticals stand at APP 2018 it was great to see you!
Read more
Femme-Tab ED 20/100 is the first low oestrogen contraceptive pill added to PBS schedule in Australia
The Pharmaceutical Benefits Scheme (Australia) has added a low oestrogen dose combined oral contraceptive (COC) pill for the first time to its schedule of subsidised medicines from 1 July 2013.
Read more
